Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Combination therapy of an inhibitor of group VIA phospholipase A2 with paclitaxel is highly effective in blocking ovarian cancer development.

Li H, Zhao Z, Antalis C, Zhao Z, Emerson R, Wei G, Zhang S, Zhang ZY, Xu Y.

Am J Pathol. 2011 Jul;179(1):452-61. doi: 10.1016/j.ajpath.2011.03.027. Epub 2011 May 17.

2.

Inhibition of Ca2+-independent phospholipase A2 decreases prostate cancer cell growth by p53-dependent and independent mechanisms.

Sun B, Zhang X, Talathi S, Cummings BS.

J Pharmacol Exp Ther. 2008 Jul;326(1):59-68. doi: 10.1124/jpet.108.138958. Epub 2008 Apr 25.

3.

Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice.

Li H, Wang D, Zhang H, Kirmani K, Zhao Z, Steinmetz R, Xu Y.

Mol Cancer Ther. 2009 Jun;8(6):1692-701. doi: 10.1158/1535-7163.MCT-08-1106. Epub 2009 Jun 9.

4.

Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells.

Ren J, Xiao YJ, Singh LS, Zhao X, Zhao Z, Feng L, Rose TM, Prestwich GD, Xu Y.

Cancer Res. 2006 Mar 15;66(6):3006-14.

5.

Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.

Do TV, Xiao F, Bickel LE, Klein-Szanto AJ, Pathak HB, Hua X, Howe C, O'Brien SW, Maglaty M, Ecsedy JA, Litwin S, Golemis EA, Schilder RJ, Godwin AK, Connolly DC.

Oncogene. 2014 Jan 30;33(5):539-49. doi: 10.1038/onc.2012.632. Epub 2013 Jan 21.

6.

Group VIA phospholipase A2 in both host and tumor cells is involved in ovarian cancer development.

Li H, Zhao Z, Wei G, Yan L, Wang D, Zhang H, Sandusky GE, Turk J, Xu Y.

FASEB J. 2010 Oct;24(10):4103-16. doi: 10.1096/fj.10-161356. Epub 2010 Jun 8. Erratum in: FASEB J. 2015 Jan;29(1):354.

7.

KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells.

Kim KH, Xie Y, Tytler EM, Woessner R, Mor G, Alvero AB.

J Transl Med. 2009 Jul 20;7:63. doi: 10.1186/1479-5876-7-63.

8.

Regulation of PSA secretion and survival signaling by calcium-independent phopholipase A(2)beta in prostate cancer cells.

Nicotera TM, Schuster DP, Bourhim M, Chadha K, Klaich G, Corral DA.

Prostate. 2009 Sep 1;69(12):1270-80. doi: 10.1002/pros.20968.

PMID:
19475654
9.

Picropodophyllin inhibits epithelial ovarian cancer cells in vitro and in vivo.

Lu X, Wang L, Mei J, Wang X, Zhu X, Zhang Q, Lv J.

Biochem Biophys Res Commun. 2013 Jun 7;435(3):385-90. doi: 10.1016/j.bbrc.2013.04.097. Epub 2013 May 9.

PMID:
23665331
10.

Calcium-independent phospholipase A2 beta is dispensable in inflammasome activation and its inhibition by bromoenol lactone.

Franchi L, Chen G, Marina-Garcia N, Abe A, Qu Y, Bao S, Shayman JA, Turk J, Dubyak GR, Núñez G.

J Innate Immun. 2009;1(6):607-17. doi: 10.1159/000227263.

11.

Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells.

Song Y, Wilkins P, Hu W, Murthy KS, Chen J, Lee Z, Oyesanya R, Wu J, Barbour SE, Fang X.

Biochem J. 2007 Sep 15;406(3):427-36.

12.
13.
15.
16.

Interaction between VEGF and calcium-independent phospholipase A2 in proliferation and migration of retinal pigment epithelium.

Kehler AK, Andersen C, Andreasen JR, Vohra R, Junker N, Poulsen KA, Kolko M.

Curr Eye Res. 2012 Jun;37(6):500-7. doi: 10.3109/02713683.2012.663855.

PMID:
22577768
17.

Induction of group VIA phospholipase A2 activity during in vitro ischemia in C2C12 myotubes is associated with changes in the level of its splice variants.

Poulsen KA, Pedersen SF, Kolko M, Lambert IH.

Am J Physiol Cell Physiol. 2007 Nov;293(5):C1605-15. Epub 2007 Sep 5.

18.

Roles of phospholipase A2 isoforms in swelling- and melittin-induced arachidonic acid release and taurine efflux in NIH3T3 fibroblasts.

Pedersen SF, Poulsen KA, Lambert IH.

Am J Physiol Cell Physiol. 2006 Dec;291(6):C1286-96. Epub 2006 Jul 19.

19.

Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.

Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Natali PG, Bagnato A.

Can J Physiol Pharmacol. 2010 Jun;88(6):676-81. doi: 10.1139/Y10-053.

20.

Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.

Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6966-71.

Items per page

Supplemental Content

Write to the Help Desk